Loading clinical trials...
Loading clinical trials...
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Conditions
Interventions
QAW039
QAW039
+1 more
Locations
163
United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
San Jose, California, United States
Novartis Investigative Site
Stockton, California, United States
Novartis Investigative Site
Colorado Springs, Colorado, United States
Novartis Investigative Site
Denver, Colorado, United States
Novartis Investigative Site
Winter Park, Florida, United States
Start Date
December 3, 2015
Primary Completion Date
July 4, 2019
Completion Date
August 2, 2019
Last Updated
May 3, 2021
NCT06979323
NCT07431021
NCT07383896
NCT07282886
NCT07356310
NCT06003569
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions